Lantheus Holdings announced positive results from two pivotal Phase 3 studies of TAUKLARIFY™ (florquinitau F 18 injection), a PET imaging agent. Presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 meeting, the studies assessed the agent's ability to identify tau neurofibrillary tangle (NFT) pathology in adults with cognitive impairment being evaluated for Alzheimer's disease.

In both studies, all five independent readers met the pre-specified primary endpoints for sensitivity and specificity. The studies also showed high inter-reader agreement.

Tau NFTs are closely associated with cognitive decline in Alzheimer's disease. Reliable detection may be particularly important in earlier stages of the disease. Lantheus said the findings may give clinicians a clearer view of disease progression.